CN108778344A - 抗流感病毒的泛基因型药剂和其使用方法 - Google Patents

抗流感病毒的泛基因型药剂和其使用方法 Download PDF

Info

Publication number
CN108778344A
CN108778344A CN201780014078.0A CN201780014078A CN108778344A CN 108778344 A CN108778344 A CN 108778344A CN 201780014078 A CN201780014078 A CN 201780014078A CN 108778344 A CN108778344 A CN 108778344A
Authority
CN
China
Prior art keywords
seq
lna
virus
oligonucleotide
vrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780014078.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·格伦
R·哈吉
E·范姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN108778344A publication Critical patent/CN108778344A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780014078.0A 2016-03-02 2017-03-01 抗流感病毒的泛基因型药剂和其使用方法 Pending CN108778344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302548P 2016-03-02 2016-03-02
US62/302,548 2016-03-02
PCT/US2017/020241 WO2017151795A1 (en) 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same

Publications (1)

Publication Number Publication Date
CN108778344A true CN108778344A (zh) 2018-11-09

Family

ID=59743201

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780014078.0A Pending CN108778344A (zh) 2016-03-02 2017-03-01 抗流感病毒的泛基因型药剂和其使用方法

Country Status (17)

Country Link
US (1) US10597658B2 (https=)
EP (3) EP3800257B1 (https=)
JP (3) JP7536272B2 (https=)
CN (1) CN108778344A (https=)
CA (1) CA3014776A1 (https=)
DK (1) DK3800257T3 (https=)
ES (1) ES2981765T3 (https=)
FI (1) FI3800257T3 (https=)
HR (1) HRP20240765T1 (https=)
HU (1) HUE066977T2 (https=)
LT (1) LT3800257T (https=)
PL (1) PL3800257T3 (https=)
PT (1) PT3800257T (https=)
RS (1) RS65707B1 (https=)
SI (1) SI3800257T1 (https=)
SM (1) SMT202400253T1 (https=)
WO (1) WO2017151795A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712928A (zh) * 2009-11-13 2012-10-03 Avi生物制药公司 反义抗病毒化合物及治疗流感病毒感染的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT69956A (en) * 1990-08-14 1995-09-28 Isis Pharmaceuticals Inc Methode for inhibition of influenza virus by antiseuse oligonucleotides
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
AU2006235364A1 (en) * 2005-04-08 2006-10-19 Marina Biotech, Inc. RNAi therapeutic for respiratory virus infection
EP1937066A4 (en) * 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
CA2666657A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20090042823A1 (en) 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza
CA2729757A1 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
AU2009310557B2 (en) * 2008-10-27 2014-09-11 Academisch Ziekenhuis Leiden Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
EP2519633B1 (en) * 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CA2800281C (en) * 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712928A (zh) * 2009-11-13 2012-10-03 Avi生物制药公司 反义抗病毒化合物及治疗流感病毒感染的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIMONE GIANNECCHINI等: "Oligonucleotides derived from the packaging signal at the 5" end of the viral PB2 segment specifically inhibit influenza virus in vitro", 《ARCH VRIOL》 *
YI JIN等: "Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib", 《THE JOURNAL OF GENE MEDICINE》 *

Also Published As

Publication number Publication date
PL3800257T3 (pl) 2024-09-16
DK3800257T3 (da) 2024-06-24
HRP20240765T1 (hr) 2024-09-13
EP3423107A4 (en) 2020-01-15
JP2025096365A (ja) 2025-06-26
SMT202400253T1 (it) 2024-09-16
RS65707B1 (sr) 2024-08-30
US10597658B2 (en) 2020-03-24
JP2022176378A (ja) 2022-11-25
WO2017151795A1 (en) 2017-09-08
EP3800257A1 (en) 2021-04-07
EP4389221A3 (en) 2024-11-20
LT3800257T (lt) 2024-07-25
HUE066977T2 (hu) 2024-09-28
JP2019511471A (ja) 2019-04-25
EP4389221A2 (en) 2024-06-26
CA3014776A1 (en) 2017-09-08
JP7536272B2 (ja) 2024-08-20
US20190136242A1 (en) 2019-05-09
ES2981765T3 (es) 2024-10-10
EP3423107A1 (en) 2019-01-09
PT3800257T (pt) 2024-06-26
EP3800257B1 (en) 2024-05-01
FI3800257T3 (fi) 2024-06-19
SI3800257T1 (sl) 2025-04-30

Similar Documents

Publication Publication Date Title
Groenke et al. Mechanism of virus attenuation by codon pair deoptimization
Steinhauer et al. Genetics of influenza viruses
Fonville et al. Influenza virus reassortment is enhanced by semi-infectious particles but can be suppressed by defective interfering particles
JP2025096365A (ja) インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
Szabat et al. RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication
Shah Mahmud et al. Bacterial ribonuclease binase exerts an intra-cellular anti-viral mode of action targeting viral RNAs in influenza a virus-infected MDCK-II cells
WO2021201996A1 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
Motard et al. A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease
US20240425852A1 (en) Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
US12618063B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
Giannecchini et al. Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro
Giannecchini et al. Packaging signals in the 5′-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules
HK40113249A (en) Pan-genotypic agents against influenza virus and methods of using the same
EP4464779A2 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
WO2025059148A1 (en) Agents against respiratory viruses and methods of using the same
HK40118855A (en) Pan-genotypic agents against respiratory viruses and methods of using the same
HK40091735A (zh) 抗呼吸道病毒的泛基因型药剂及其使用方法
HK1262033A1 (en) Pan-genotypic agents against influenza virus and methods of using the same
Hagey et al. Identification and targeting of a pan-genotypic influenza A virus RNA structure that mediates packaging and disease
US11046958B2 (en) Antisense oligonucleotides that inhibit influenza virus replication and uses thereof
Winn The role of host factor Transportins in Influenza virus entry and infection
Hauck No escape mutants and decreased variability of viral quasispecies after immunization against long alpha helix of pandemic H1N1 in a mouse model study

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262033

Country of ref document: HK